Cargando…

Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery

Background and purpose: Although patients with esophageal squamous cell carcinoma (ESCC) can achieve a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) followed by surgery, one-third of these patients with a pCR may still experience recurrence. The aim of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Qingtao, Duan, Jinghao, Deng, Hongbin, Han, Zhujun, Gu, Jiabing, Yue, Ning J., Yin, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431604/
https://www.ncbi.nlm.nih.gov/pubmed/32850451
http://dx.doi.org/10.3389/fonc.2020.01398
_version_ 1783571617606008832
author Qiu, Qingtao
Duan, Jinghao
Deng, Hongbin
Han, Zhujun
Gu, Jiabing
Yue, Ning J.
Yin, Yong
author_facet Qiu, Qingtao
Duan, Jinghao
Deng, Hongbin
Han, Zhujun
Gu, Jiabing
Yue, Ning J.
Yin, Yong
author_sort Qiu, Qingtao
collection PubMed
description Background and purpose: Although patients with esophageal squamous cell carcinoma (ESCC) can achieve a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) followed by surgery, one-third of these patients with a pCR may still experience recurrence. The aim of this study is to develop and validate a predictive model to estimate recurrence-free survival (RFS) in those patients who achieved pCR. Materials and methods: Two hundred six patients with ESCC were enrolled and divided into a training cohort (n = 146) and a validation cohort (n = 60). Radiomic features were extracted from contrast-enhanced computed tomography (CT) images of each patient. Feature reduction was then implemented in two steps, including a multiple segmentation test and least absolute shrinkage and selection operator (LASSO) Cox proportional hazards regression method. A radiomics signature was subsequently constructed and evaluated. For better prediction performance, a clinical nomogram based on clinical risk factors and a nomogram incorporating the radiomics signature and clinical risk factors was built. Finally, the prediction models were further validated by calibration and the clinical usefulness was examined in the validation cohort to determine the optimal prediction model. Results: The radiomics signature was constructed using eight radiomic features and displayed a significant correlation with RFS. The nomogram incorporating the radiomics signature with clinical risk factors achieved optimal performance compared with the radiomics signature (P < 0.001) and clinical nomogram (P < 0.001) in both the training cohort [C-index (95% confidence interval [CI]), 0.746 (0.680–0.812) vs. 0.685 (0.620–0.750) vs. 0.614 (0.538–0.690), respectively] and validation cohort [C-index (95% CI), 0.724 (0.696–0.752) vs. 0.671 (0.624–0.718) vs. 0.629 (0.597–0.661), respectively]. The calibration curve and decision curve analysis revealed that the radiomics nomogram outperformed the other two models. Conclusions: A radiomics nomogram model incorporating radiomics features and clinical factors has been developed and has the improved ability to predict the postoperative recurrence risk in patients with ESCC who achieved pCR after nCRT followed by surgery.
format Online
Article
Text
id pubmed-7431604
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74316042020-08-25 Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery Qiu, Qingtao Duan, Jinghao Deng, Hongbin Han, Zhujun Gu, Jiabing Yue, Ning J. Yin, Yong Front Oncol Oncology Background and purpose: Although patients with esophageal squamous cell carcinoma (ESCC) can achieve a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) followed by surgery, one-third of these patients with a pCR may still experience recurrence. The aim of this study is to develop and validate a predictive model to estimate recurrence-free survival (RFS) in those patients who achieved pCR. Materials and methods: Two hundred six patients with ESCC were enrolled and divided into a training cohort (n = 146) and a validation cohort (n = 60). Radiomic features were extracted from contrast-enhanced computed tomography (CT) images of each patient. Feature reduction was then implemented in two steps, including a multiple segmentation test and least absolute shrinkage and selection operator (LASSO) Cox proportional hazards regression method. A radiomics signature was subsequently constructed and evaluated. For better prediction performance, a clinical nomogram based on clinical risk factors and a nomogram incorporating the radiomics signature and clinical risk factors was built. Finally, the prediction models were further validated by calibration and the clinical usefulness was examined in the validation cohort to determine the optimal prediction model. Results: The radiomics signature was constructed using eight radiomic features and displayed a significant correlation with RFS. The nomogram incorporating the radiomics signature with clinical risk factors achieved optimal performance compared with the radiomics signature (P < 0.001) and clinical nomogram (P < 0.001) in both the training cohort [C-index (95% confidence interval [CI]), 0.746 (0.680–0.812) vs. 0.685 (0.620–0.750) vs. 0.614 (0.538–0.690), respectively] and validation cohort [C-index (95% CI), 0.724 (0.696–0.752) vs. 0.671 (0.624–0.718) vs. 0.629 (0.597–0.661), respectively]. The calibration curve and decision curve analysis revealed that the radiomics nomogram outperformed the other two models. Conclusions: A radiomics nomogram model incorporating radiomics features and clinical factors has been developed and has the improved ability to predict the postoperative recurrence risk in patients with ESCC who achieved pCR after nCRT followed by surgery. Frontiers Media S.A. 2020-08-11 /pmc/articles/PMC7431604/ /pubmed/32850451 http://dx.doi.org/10.3389/fonc.2020.01398 Text en Copyright © 2020 Qiu, Duan, Deng, Han, Gu, Yue and Yin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qiu, Qingtao
Duan, Jinghao
Deng, Hongbin
Han, Zhujun
Gu, Jiabing
Yue, Ning J.
Yin, Yong
Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery
title Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery
title_full Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery
title_fullStr Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery
title_full_unstemmed Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery
title_short Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery
title_sort development and validation of a radiomics nomogram model for predicting postoperative recurrence in patients with esophageal squamous cell cancer who achieved pcr after neoadjuvant chemoradiotherapy followed by surgery
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431604/
https://www.ncbi.nlm.nih.gov/pubmed/32850451
http://dx.doi.org/10.3389/fonc.2020.01398
work_keys_str_mv AT qiuqingtao developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery
AT duanjinghao developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery
AT denghongbin developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery
AT hanzhujun developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery
AT gujiabing developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery
AT yueningj developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery
AT yinyong developmentandvalidationofaradiomicsnomogrammodelforpredictingpostoperativerecurrenceinpatientswithesophagealsquamouscellcancerwhoachievedpcrafterneoadjuvantchemoradiotherapyfollowedbysurgery